Literature DB >> 12150848

Could widespread use of combination antiretroviral therapy eradicate HIV epidemics?

J X Velasco-Hernandez1, H B Gershengorn, S M Blower.   

Abstract

Current combination antiretroviral therapies (ARV) are widely used to treat HIV. However drug-resistant strains of HIV have quickly evolved, and the level of risky behaviour has increased in certain communities. Hence, currently the overall impact that ARV will have on HIV epidemics remains unclear. We have used a mathematical model to predict whether the current therapies: are reducing the severity of HIV epidemics, and could even lead to eradication of a high-prevalence (30%) epidemic. We quantified the epidemic-level impact of ARV on reducing epidemic severity by deriving the basic reproduction number (R(0)(ARV)). R(0)(ARV) specifies the average number of new infections that one HIV case generates during his lifetime when ARV is available and ARV-resistant strains can evolve and be transmitted; if R(0)(ARV) is less than one epidemic eradication is possible. We estimated for the HIV epidemic in the San Francisco gay community (using uncertainty analysis), the present day value of R(0)(ARV), and the probability of epidemic eradication. We assumed a high usage of ARV and three behavioural assumptions: that risky sex would (1) decrease, (2) remain stable, or (3) increase. Our estimated values of R(0)(ARV) (median and interquartile range [IQR]) were: 0.90 (0.85-0.96) if risky sex decreases, 1.0 (0.94-1.05) if risky sex remains stable, and 1.16 (1.05-1.28) if risky sex increases. R(0)(ARV) decreased as the fraction of cases receiving treatment increased. The probability of epidemic eradication is high (p=0.85) if risky sex decreases, moderate (p=0.5) if levels of risky sex remain stable, and low (p=0.13) if risky sex increases. We conclude that ARV can function as an effective HIV-prevention tool, even with high levels of drug resistance and risky sex. Furthermore, even a high-prevalence HIV epidemic could be eradicated using current ARV.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12150848     DOI: 10.1016/s1473-3099(02)00346-8

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  80 in total

1.  An assessment of preferential attachment as a mechanism for human sexual network formation.

Authors:  James Holland Jones; Mark S Handcock
Journal:  Proc Biol Sci       Date:  2003-06-07       Impact factor: 5.349

2.  Changes in sexual behavior among HIV-infected women after initiation of HAART.

Authors:  Tracey E Wilson; Mary Elizabeth Gore; Ruth Greenblatt; Mardge Cohen; Howard Minkoff; Sylvia Silver; Esther Robison; Alexandra Levine; Stephen J Gange
Journal:  Am J Public Health       Date:  2004-07       Impact factor: 9.308

3.  HIV Treatment in Resource-Limited Environments: Treatment Coverage and Insights.

Authors:  Amin Khademi; Denis Saure; Andrew Schaefer; Kimberly Nucifora; R Scott Braithwaite; Mark S Roberts
Journal:  Value Health       Date:  2015-11-12       Impact factor: 5.725

4.  Should we try to eliminate HIV epidemics by using a 'Test and Treat' strategy?

Authors:  Bradley G Wagner; James S Kahn; Sally Blower
Journal:  AIDS       Date:  2010-03-13       Impact factor: 4.177

5.  Evidence-based modeling of critical illness: an initial consensus from the Society for Complexity in Acute Illness.

Authors:  Yoram Vodovotz; Gilles Clermont; C Anthony Hunt; Rolf Lefering; John Bartels; Ruediger Seydel; John Hotchkiss; Shlomo Ta'asan; Edmund Neugebauer; Gary An
Journal:  J Crit Care       Date:  2007-03       Impact factor: 3.425

Review 6.  Does antiretroviral therapy prevent HIV transmission to sexual partners?

Authors:  Tahaniyat Lalani; Charles Hicks
Journal:  Curr HIV/AIDS Rep       Date:  2007-05       Impact factor: 5.071

7.  Biological and demographic causes of high HIV and sexually transmitted disease prevalence in men who have sex with men.

Authors:  Steven M Goodreau; Matthew R Golden
Journal:  Sex Transm Infect       Date:  2007-09-13       Impact factor: 3.519

Review 8.  Is expanded HIV treatment preventing new infections? Impact of antiretroviral therapy on sexual risk behaviors in the developing world.

Authors:  Kartik K Venkatesh; Timothy P Flanigan; Kenneth H Mayer
Journal:  AIDS       Date:  2011-10-23       Impact factor: 4.177

9.  Does antiretroviral therapy prevent HIV transmission to sexual partners?

Authors:  Tahaniyat Lalani; Charles Hicks
Journal:  Curr Infect Dis Rep       Date:  2008-05       Impact factor: 3.725

10.  Transient virulence of emerging pathogens.

Authors:  Benjamin M Bolker; Arjun Nanda; Dharmini Shah
Journal:  J R Soc Interface       Date:  2009-10-28       Impact factor: 4.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.